Document:

Exhibit 10.8

 

PATENT ASSIGNMENT AGREEMENT

 

THIS PATENT ASSIGNMENT
AGREEMENT (this “Agreement”) is dated as of April 1 , 2022 (“Effective Date”), and is made by and between
HESP LLC, a Delaware limited liability company (“Assignor”), and Cadrenal Therapeutics Inc., a Delaware corporation
(“Assignee”). Each of Assignor and Assignee may be referenced herein as a “Party,” and collectively, the
“Parties.”

 

W I T N E S S E T H :

 

WHEREAS,
pursuant to that certain Asset Purchase Agreement between Assignor and Assignee dated on or about the date hereof (the “Purchase
Agreement”), Assignor has agreed to (and cause its applicable Affiliates to) sell, convey, assign and transfer to Assignee,
at the Closing, the Purchased Assets, including the patents listed on Schedule A hereto (the “Assigned Patents”); and

 

WHEREAS,
as a condition to the Closing, the Parties agreed to enter into this Agreement pursuant to which Assignor shall assign to Assignee all
of Assignor’s right, title and interest in, to and under the Assigned Patents, as the case may be.

 

NOW, THEREFORE,
for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:

 

1. Defined
Terms; Interpretation. Capitalized terms used but not defined herein shall have the meanings given to them in the Purchase Agreement.

 

2. Assignment
of Rights in Assigned Patents. Effective upon the Effective Date, Assignor hereby sells, conveys, assigns and transfers to Assignee,
and Assignee hereby accepts, all of Assignor’s right, title and interest in, to and under (a) the Assigned Patents, (b) all applications
and registrations for the Assigned Patents, together with all non-provisionals, reissuances, continuations, continuations-in-part, divisionals,
revisions, extensions and reexaminations with respect thereto, and any other applications and patents claiming priority thereto, both
in the United States and other jurisdictions, and (c) any and all rights, benefits, privileges and proceeds under the Assigned Patents
throughout the world, including (i) any claim by Assignor against third parties for past, present or future infringement of the Assigned
Patents, and the right to sue for and collect the same for Assignee’s own use and enjoyment, all to be held and enjoyed by Assignee,
its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor had the assignment not been
made, (ii) the exclusive right to apply for, maintain and claim priority from all registrations, renewals or extensions thereof, (iii)
the exclusive right to grant licenses or other interests therein, (iv) the right to claim priority in all countries in accordance with
international law, (v) the right to collect royalties and proceeds in connection with any of the foregoing and (vi) to apply for, prosecute,
and seek patents throughout the world in respect of any inventions to the extent fully supported by the Assigned Patents.

 

3. Recording.
Assignor hereby requests the Commissioner of Patents and Trademarks and the corresponding entities or agencies in any other
applicable countries to record Assignee as the assignee and owner of the Assigned Patents, including any continuations, divisionals,
continuations-in-part, registrations, reissues, reexaminations or extensions thereof, and to issue any and all letters patent
thereon to Assignee, as assignee of the entire right, title and interest in, to and under the same, for the sole use and enjoyment
of Assignee, its successors, assigns or other legal representatives.

 

     

     

    

 

4. Assistance.
Assignor shall not execute any writing or do any act whatsoever conflicting with the terms and conditions of this Agreement. Furthermore,
Assignor will, upon reasonable request, without further or additional consideration, but at the expense of Assignee, execute, acknowledge
and deliver, or cause to be executed, acknowledged and delivered, such additional instruments, notices, releases, certificates, powers
of attorney, assurances, bills of sale and other documents and do such further acts, assignments, transfers and other things, in each
case, as reasonably necessary to transfer to Assignee the Assigned Patents, to vest and confirm in Assignee the legal title to the Assigned
Patents, and to perfect Assignee’s enjoyment of this grant.

 

5. Miscellaneous.
This Agreement is executed and delivered pursuant to, is in accordance with, and is subject to, all of the representations, warranties,
covenants and indemnities set forth in the Purchase Agreement, all of which shall survive the consummation of the transactions contemplated
hereby on the basis and to the extent set forth in the Purchase Agreement. Nothing contained in this Agreement shall in any way supersede,
modify, replace, amend, change, rescind, waive, exceed, expand, enlarge or in any way affect the provisions set forth in the Purchase
Agreement nor shall this Agreement reduce, expand or enlarge any remedies under the Purchase Agreement. In the event that any provision
of this Agreement shall be construed to conflict with a provision in the Purchase Agreement, the terms of the Purchase Agreement shall
control. This Agreement may be executed in any number of counterparts (including by facsimile or electronic transmission in .pdf, .tiff
or any similar format), each of which shall be an original, but all of such counterparts together constitute one and the same instrument,
and shall become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Party. This
Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their respective successors and assigns. This
Agreement shall be governed in all respects, including validity, interpretation, construction, performance and effect, by the internal
laws of the State of Delaware, without regard to its conflict of laws principles that would result in the application of the law of any
other state or jurisdiction. This Agreement may not be waived or amended except by an instrument in writing signed on behalf of each of
the Parties hereto.

 

[Remainder of Page Intentionally
Left Blank]

 

    2

     

    

 

IN WITNESS WHEREOF, the
undersigned has executed this Patent Assignment Agreement as of the date first set forth above.

 

	 	ASSIGNOR:
	 	 
	 	HESP LLC
	 	By:	Horizon Technology Finance Corporation,
	 	 	its sole member
	 	 	 
	 	By:	/s/ Gerald A. Michaud
	 	Name: 	Gerald A. Michaud
	 	Title:	President 

 

    3

     

    

 

IN WITNESS WHEREOF, the Assignee
has executed this Patent Assignment Agreement as of the date first set forth above.

 

	 	ASSIGNEE:
	 	 
	 	CADRENAL THERAPEUTICS INC.
	 	 	 
	 	By:	/s/ Quang Pham
	 	Name: 	Quang Pham
	 	Title:	Chief Executive Officer

 

    4

     

    

 

Schedule A

 

Assigned Patents

 

For the avoidance of doubt, the Assigned Patents includes (i)
any substitutions, extensions, additions, reissues, reexaminations, renewals, divisions, continuations, continuations-in-part, or supplementary
protection certificates, or patents or pending patent applications claiming priority, to the following patents, and (ii) all foreign counterparts
of any of the following patents or those listed in clause (i).

 

	Country	Application #	Owner	Application Date
	U.S.A.	62/323,904	Espero Pharmaceuticals, Inc.	04/18/2016
	U.S.A.	PCT/US2017/027887	Espero Pharmaceuticals, Inc.	04/17/2017
	U.S.A.	15/131,446	Espero Pharmaceuticals, Inc.	04/18/2016
	U.S.A.	PCT/US2017/027883	Espero Pharmaceuticals, Inc.	04/18/2017
	U.S.A.	15/131,478	Espero Pharmaceuticals, Inc.	04/18/2016
	U.S.A.	PCT/US2017/027886	Espero Pharmaceuticals, Inc.	04/17/2017
	Country	Registration #	Owner	Registration Date
	Tecarfarin
	U.S.A.	7666902	Espero BioPharma, Inc.	02/23/2010
	U.S.A.	7145020	Espero BioPharma, Inc.	12/05/2006
	Country	Application #	Owner	Application Date
	U.S.A.	7932405	Espero BioPharma, Inc.	04/26/2011
	U.S.A.	7253208	Espero BioPharma, Inc.	08/07/2007
	U.S.A.	7285671	Espero BioPharma, Inc.	10/23/2007
	Australia	2005233614	Espero BioPharma, Inc.	7/12/2012
	Austria	1735296	Espero BioPharma, Inc.	12/9/2009
	Belgium	1735296	Espero BioPharma, Inc.	12/9/2009
	Belgium	2161261	Espero BioPharma, Inc.	8/28/2013
	Brazil	PI0508392-3	Espero BioPharma, Inc.	 
	Canada	2559568	Espero BioPharma, Inc.	5/28/2013
	China	200580012074.6	Espero BioPharma, Inc.	6/1/2011
	Cyprus	1735296	Espero BioPharma, Inc.	12/9/2009
	Denmark	1735296	Espero BioPharma, Inc.	12/9/2009
	Denmark	2161261	Espero BioPharma, Inc.	8/28/2013

 

    A-1

     

    

 

	Country	Application #	Owner	Application Date
	Europe	05733799.0	Espero BioPharma, Inc.	12/9/2009
	Europe	09175606.4	Espero BioPharma, Inc.	8/28/2013
	Finland	1735296	Espero BioPharma, Inc.	12/9/2009
	Finland	2161261	Espero BioPharma, Inc.	8/28/2013
	France	1735296	Espero BioPharma, Inc.	12/9/2009
	France	2161261	Espero BioPharma, Inc.	8/28/2013
	Germany	602005018181.4	Espero BioPharma, Inc.	12/9/2009
	Germany	602005041073.2	Espero BioPharma, Inc.	8/28/2013
	Great Britain	1735296	Espero BioPharma, Inc.	12/9/2009
	Great Britain	2161261	Espero BioPharma, Inc.	8/28/2013
	Greece	3071104	Espero BioPharma, Inc.	12/9/2009
	Hong Kong	1105200	Espero BioPharma, Inc.	3/9/2012
	Hong Kong	1138265	Espero BioPharma, Inc.	5/23/2014
	India	250594	Espero BioPharma, Inc.	1/11/2012
	Ireland	1735296	Espero BioPharma, Inc.	12/9/2009
	Ireland	2161261	Espero BioPharma, Inc.	8/28/2013
	Israel	178122	Espero BioPharma, Inc.	5/4/2013
	Israel	DIVOF178122	Espero BioPharma, Inc.	 
	Italy	502010901815570	Espero BioPharma, Inc.	12/9/2009
	Italy	502013902212109	Espero BioPharma, Inc.	8/28/2013
	Japan	5036532	Espero BioPharma, Inc.	7/13/2012
	Luxembourg	1735296	Espero BioPharma, Inc.	12/9/2009
	Luxembourg	2161261	Espero BioPharma, Inc.	8/28/2013
	Mexico	274321	Espero BioPharma, Inc.	5/3/2010
	Monaco	1735296	Espero BioPharma, Inc.	12/9/2009
	Monaco	2161261	Espero BioPharma, Inc.	8/28/2013
	Netherlands	1735296	Espero BioPharma, Inc.	12/9/2009
	Netherlands	2161261	Espero BioPharma, Inc.	8/28/2013
	Norway	338837	Espero BioPharma, Inc.	10/24/2016
	Philippines	1-2006-501866	Espero BioPharma, Inc.	11/19/2010
	Portugal	1735296	Espero BioPharma, Inc.	12/9/2009
	Russia	2335501	Espero BioPharma, Inc.	10/10/2008
	Russia	2006/07667	Espero BioPharma, Inc.	10/10/2013
	South Africa	2006/07667	Espero BioPharma, Inc.	11/28/2007
	South Korea	1203124	Espero BioPharma, Inc.	11/14/2012
	Spain	05733799.0	Espero BioPharma, Inc.	12/9/2009
	Spain	09175606.4	Espero BioPharma, Inc.	8/28/2013
	Sweden	05733799.0	Espero BioPharma, Inc.	12/9/2009
	Sweden	09175606.4	Espero BioPharma, Inc.	8/28/2013
	Switzerland	1735296	Espero BioPharma, Inc.	12/9/2009
	Switzerland	2161261	Espero BioPharma, Inc.	8/28/2013

 

 

A-2Exhibit 10.9

  

SUBSCRIPTION AGREEMENT

 

Cadrenal Therapeutics, Inc.

822 A1A North, Suite 320

Ponte Vedra, Florida 32082

 

Gentlemen:

 

I hereby apply to Cadrenal
Therapeutics, Inc., a Delaware corporation (hereinafter “you” or “Company”), to purchase the shares of common
stock, par value $0.001, being offered by the Company (“Common Stock”) indicated on the signature page to this Agreement (the
“Shares”). I understand that you may at any time at your sole discretion reject this subscription, and that you will advise
me as soon as practicable if my subscription has not been accepted or if the offering of your common stock is withdrawn. If you reject
my subscription or withdraw the offering, you will promptly return to me all amounts delivered by me in payment for the Shares and this
subscription agreement will have no further effect. If you reject my subscription, I will return to you any documents you have provided
to me at my request for the purpose of evaluating this offering. If you accept my subscription, you will promptly provide me the stock
certificate representing the Shares that I purchase in this offering.

 

1.
Representations of Subscriber. As an inducement to you to sell me the Shares for which I have subscribed, I hereby
represent to you as follows (either in my individual capacity or as an authorized representative of an entity, as applicable), on the
understanding that those representations will survive receipt (or the receipt by such entity) of the Shares:

 

		(1)	If an individual, I am a bona fide resident of the state set forth on the last page of this Agreement,
over 21 years of age, and legally competent to execute this Agreement; if an entity, the person executing this Agreement on my behalf
represents that the entity is duly organized under the laws of the state set forth on the last page of this Agreement, the entity is validly
existing, and I have full power and authority to execute this Agreement, which will then be my legal, valid and binding agreement;

 

		(2)	I have been furnished and have read all written materials provided by you relating to you, your proposed
operations, the private offering of the Shares and any other matters relating to this private offering (all such materials, including
the Company’s private placement memorandum hereinafter collectively called the “offering materials”) which have been
requested; you have answered all inquiries that I have put to you relating thereto; and I have been afforded the opportunity to obtain
any additional information, to the extent you possessed such information or were able to acquire it without unreasonable effort or expense,
necessary (a) to verify the accuracy of the information set forth in the offering materials; and (b) to evaluate the merits
and risks of purchasing the Shares;

 

		(3)	I have carefully reviewed and understand the various risks of an investment in the Shares and have made
such independent investigation and evaluation of all written materials provided to me by you with respect to your financial condition,
properties, business and prospects as I deem necessary to make an informed decision to purchase the Shares; my decision to purchase the
Shares has been made on the basis of such investigation and evaluation; in making such decision I have relied exclusively on the written
statements with respect to any such matters or otherwise with respect to you which are contained in the offering materials, and which
have been independently investigated and evaluated by me;

 

     

     

    

 

		(4)	I have completed the confidential prospective purchaser questionnaire; I confirm the statements made therein
are true on the date hereof, and I acknowledge that the statements and representations made by me therein and in this Agreement have been
relied upon by you in offering to sell the Shares to me; I further agree to indemnify and hold harmless the Company and its respective
officers, directors and stockholders, from any and all damages, losses, costs and expenses (including reasonable attorneys’ fees)
that they may incur, by reason of any breach of any of the statements or representations made by me contained herein or therein;

 

		(5)	I acknowledge that although you may effect a public offering of your common stock, no assurances have
been given to me that any such offering will ever take place.;

 

		(6)	I realize that I will not be able to resell readily any of the Shares purchased under this Agreement because
none of the Shares have been registered under the Securities Act of 1933, as amended (the “Act”), or any state securities
laws, and, therefore, those securities can be sold only if they are subsequently registered under the Act or an exemption from registration
is available;

 

		(7)	I understand that you have the absolute right to refuse to consent to transfer or assignment of any securities
if that transfer or assignment does not comply with applicable state and federal securities laws;

 

		(8)	I understand that this offering is intended to be a non-public offering in accordance with section 4(a)(2)
of the Act and Regulation D promulgated under the Act (“Regulation D”), that no aspect of this offering has been reviewed
by the United States Securities and Exchange Commission or the securities regulatory authorities of any state and that none of the offering
materials nor any other written materials furnished by you and used in connection with this offering has been reviewed by any federal
or state securities regulatory bodies or authorities;

 

		(9)	The Shares are being purchased for my own account, for investment, and not with a view to distribution
or resale to others; I am not participating, directly or indirectly in an underwriting of any such distribution or other transfer; I do
not now have reason to anticipate any change in my circumstances or any other particular occasion or event which would cause me to sell
the Shares (or the components thereof); I have substantial experience in making decisions of this type or am relying on my own qualified
advisor in making the investment decision; and I understand that you are relying upon the truth and accuracy of this representation and
warranty;

 

		(10)	Neither you nor any person acting on your behalf has made any representations to me except as contained
in the offering materials; and in making my decision to purchase the Shares I have subscribed for, I have not relied on any representations
or information other than those which I have independently investigated and verified to my satisfaction;

 

		(11)	I understand that this subscription may be accepted or rejected, in whole or in part, by you in your sole
and absolute discretion;

 

		(12)	All the information that I heretofore furnished to you, or that is set forth in this Agreement or the
related prospective purchaser questionnaire, with respect to my financial position and business experience is correct and complete as
of the date of this Agreement, and if there should be any material change in that information prior to receipt of the Shares that I subscribe
for, I will immediately furnish you with revised or corrected information;

 

		(13)	I represent that I am currently, and agree to notify you immediately in writing if I cease to be, an “accredited
investor” within the meaning of Rule 501(a) of Regulation D;

 

		(14)	I am not subject to any “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii)
of the Act;

 

		(15)	I am able to bear the substantial economic risk of an investment in the Shares and currently can afford
a complete loss of that investment; my overall commitment in investments that are not readily marketable is reasonable in relation to
my net worth; and

 

		(16)	If an entity, I have not been organized for the specific purpose of acquiring the Shares being offered.

 

    2

     

    

 

For Foreign Investors Only:

 

		(15)	If the undersigned is a foreign (non-U.S.) investor, the
undersigned represents and warrants:

 

		(a)	Neither I nor any person or entity for whom I am acting as fiduciary is a U.S. Person.
	 	 	 

		(b)	At the time the agreement to purchase was originated, I was outside the United States and is outside of the United States as of the
date of the execution and delivery of this Agreement.
	 	 	 

		(c)	I am not purchasing the Shares on behalf of any and the sale has not been prearranged with a purchaser in the United States.
	 	 	 

		(d)	All subsequent offers and sales of the Shares will be made (i) outside the United States in compliance with Rule 903 or Rule 904 of
Regulation S; (ii) pursuant to registration of the Shares under the Act; or (iii) pursuant to an exemption from such registration.

 

2.
Miscellaneous. (A) All notices or other communications given or made
under this Agreement must be in writing and be delivered by hand or mailed by registered or certified mail, postage prepaid, to myself
or to you at the respective addresses set forth herein, and will be deemed to have been given or delivered on the date of the hand delivery
or four days after mailing.

 

(b) 
All matters arising under this Agreement, including without limitations tort claims, are governed by the laws of the state
of Delaware, without giving effect to principles of conflicts of law.

 

(c) 
This Agreement constitutes the entire agreement between you and I with respect to the subject matter of this Agreement and
may be amended only by a writing executed by you and I. Neither this Agreement nor any of my rights under this Agreement may be transferred
or otherwise assigned hereunder.

 

(d) 
Unless this Agreement is rejected, my obligations hereunder will not be terminated upon the occurrence of any event (whether
by operation of law or otherwise), including, without limitation, my death, occurrence of disability, or declaration that I am incompetent,
and this Agreement (including the representations and warranties contained herein) will bind my successors, legal representatives, heirs,
and distributees.

 

(e)  
If requested at any time by you, I will promptly supply such information regarding myself as may be necessary for inclusion
in any registration, qualification, application or other filing to be made at any time hereafter on your behalf. I shall furnish such
information to you as you deem necessary to satisfy yourself that I may legally purchase the Shares.

 

    3

     

    

 

3.
Representations and Warranties of the Company. The Company represents and warrants to the subscriber as follows:

 

(a) 
The Company is duly organized and validly exists as a corporation in good standing under the laws of Delaware.

 

(b) 
The Company has the corporate power and authority to enter into, deliver and perform this Agreement.

 

(c) 
All necessary corporate action has been duly and validly taken by the company to authorize the execution, delivery and performance
of this subscription agreement, the related security agreement and the issuance of the Shares to be sold by the Company pursuant to this
Agreement.

 

(d) 
This Agreement constitutes the legal, valid and binging obligation of the Company enforceable against the Company in accordance
with its terms except as the enforceability may be limited by bankruptcy and general equitable principles.

 

(e)
The Shares are, and when issued will be, free and clear of all mortgages, pledges, liens, security interests, encumbrances,
conditional sale agreements, charges and restrictions on every kind and nature whatsoever.

 

(F) The authorized capital stock
of the Company consists of 10,000,000 shares of Common Stock.

 

(G)  The
Company is in possession of all franchises, grants, authorizations, licenses, permits, easements, variances, exemptions, consents, certificates,
approvals and orders necessary to own, lease and operate its properties and to carry on its business as it is now being conducted (collectively,
the “Company Permits”), and there is no action pending or, to the knowledge of the Company, threatened regarding suspension
or cancellation of any of the Company Permits. The Company is not in conflict with, or in default or violation of, any of the Company
Permits, except for any such conflicts, defaults or violations which, individually or in the aggregate, would not reasonably be expected
to have a Material Adverse Effect. Since January 22, 2022, the Company has not received any notification with respect to possible conflicts,
defaults or violations of applicable laws, except for notices relating to possible conflicts, defaults or violations, which conflicts,
defaults or violations would not have a Material Adverse Effect.

 

(H)  There
is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory
organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company, or its businesses, properties
or assets or their officers or directors in their capacity as such, that would have a material adverse effect on the operations or business
of the Company.

 

(I)  The
Company owns or possesses adequate rights or licenses to use all trademarks, trade names, service marks, service mark registrations, service
names, patents, patent rights, copyrights, original works, inventions, licenses, approvals, governmental authorizations, trade secrets
and other intellectual property rights and all applications and registrations therefor (“Intellectual Property Rights”)
necessary to conduct its business as now conducted and as presently proposed to be conducted. The Company has no knowledge of any infringement
by the Company of Intellectual Property Rights of others. There is no claim, action or proceeding being made or brought, or to the Company’s
knowledge, being threatened, against the Company regarding their Intellectual Property Rights.

 

(J)   The
Investor Package in connection with the June 2022 bridge financing, including the Subscription Agreement and the exhibits thereto (the
“Investor Package”) does not contain any untrue statement of a material fact or omitted to state a material fact required
to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not
misleading.

 

4.
Compliance with applicable laws. I will not sell, assign, transfer, pledge or otherwise dispose of any of the Shares
except in compliance with all conditions on transfer imposed by the Act and by “blue sky” or securities laws of any state,
and I will be fully responsible for complying with all such conditions.

 

5.
Execution of other documents. I will execute such other documents as may be necessary to complete the transactions contemplated
hereby, including, without limitation, the prospective purchaser questionnaire, and I will be bound by all of the terms of any such documents
and will perform all of my obligations thereunder with respect to the Shares being subscribed for.

 

I am entering into this Agreement
by signing the attached “individual subscription” or “entity subscription,” as applicable, on the date indicated
thereon. By so doing I am agreeing to purchase the Shares stated thereon and am agreeing to all the terms of this Agreement. I am enclosing
with this Agreement a check payable to the order of Cadrenal Therapeutics, Inc., in full payment of my subscription.

 

    4

     

    

 

Signature Page for Individuals:

 

IN WITNESS WHEREOF, Subscriber has caused this
Subscription Agreement to be executed as of the date indicated below.

 

	
    Seven Million Five Hundred Thousand
(7,500,000) 
	 	 
	
    Number of Shares Being Purchased

     

    Seven Thousand Five Hundred Dollars ($7,500.00)

    Total Purchase Price ($0.001 per Share)

     
	 	 
	Quang
    Pham	 	
	
    Print or Type Name

     
	 	
    Print or Type Name (Joint-owner)

     

	/s/ Quang Pham	 	
	
    Signature

     
	 	
    Signature (Joint-owner)

     

	1/25/22	 	
	
    Date

     
	 	
    Date (Joint-owner)

     

	xxx	 	
	
    Social Security Number

     
	 	
    Social Security Number (Joint-owner)

    

		 	
    

     

	xxx	 	
	
    Address

     
	 	Address (Joint-owner)
	xxx	 	
	
    Phone Number

     
	 	Phone Number
	xxx	 	
	Email Address	 	Email Address

 

	_______	Joint Tenancy	______ 	Tenants in Common

 

                    Tenancy
by the Entirety

 

Wiring Instructions:

 

	Bank Name:	 	xxx
	ABA #:	 	xxx
	Acct #:	 	xxx
	Acct. Name: 	 	Cadrenal Therapeutics, Inc.

 

    S-1

     

    

 

Partnerships, Corporations or Other Entities:

 

IN WITNESS WHEREOF, Subscriber has caused this
Agreement to be executed as of the date indicated below.

 

		 	 
	Total Purchase Price	 	 
	 	 	 
		 	 
	Print or Type Name of Entity	 	 
	 	 	 
		 	 
	Address	 	 
	 	 	 
		 	 
	Taxpayer I.D. No. (if applicable)	 	Date
	 	 	 
	By:	           	 	
	 	Print or Type Name	 	Title or Position with Entity
		 	
	Signature (other authorized signatory)	 	Print or Type Name and Indicate
	 	 	Title or Position with Entity

 

Wiring Instructions:

 

	Bank Name:	 	xxx
	ABA #:	 	xxx
	Acct #:	 	xxx
	Acct. Name: 	 	Cadrenal Therapeutics, Inc.

 

    S-2

     

    

 

[Company Execution Page for Subscription Agreement]

 

IN WITNESS WHEREOF, the Company has caused this
Agreement to be executed, and the foregoing subscription accepted, as of the date indicated below.

 

	 	CADRENAL THERAPEUTICS, INC.
	 	 
	 	By:	/s/
    Quang Pham
	 	Name:	Quang Pham 
	 	Title: 	Chief Executive Officer 

 

Date: January 25, 2022

 

 

S-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]